(Q44538922)

English

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?

scientific article published on 11 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression? (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Tilman Todenhöfer

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jörg Hennenlotter

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ursula Kühs

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Valentina Gerber

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Georgios Gakis

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ulrich Vogel

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Stefan Aufderklamm

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Axel Merseburger

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Judith Knapp

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Arnulf Stenzl

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Christian Schwentner

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

11 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

345-350

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

https://scigraph.springernature.com/pub.10.1007/s00345-012-0844-y

0 references

Bisphosphonates: the first 40 years

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Tissue microarrays: applications in urological cancer research.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

A clinical review of statins and cancer: helpful or harmful?

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Statin use and prostate cancer risk in a large population-based setting

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-0844-Y

21 January 2018

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate cancer: time to trial statins?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid induces autophagic cell death in human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/22407328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-012-0844-Y

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

release_cmofetbp7fhytarka5vct2v4nm

1 reference

https://api.fatcat.wiki/v0/release/cmofetbp7fhytarka5vct2v4nm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44538922&oldid=1843814726"